hylenex logo Baxter wordmark
This site is Intended for US Healthcare Professionals
Site Map  |  Contact Us  |  Request More Information  |  Buying Information
Send Sub-Q to the rescue

In the Ambulatory Surgery Center (ASC)

This overview is intended solely for use as an informational tool to assist hospital billing staff with reimbursement issues. The coverage, coding, and payment information included in the overview is subject to change and should not be construed as legal advice. Providers should exercise independent clinical judgment when selecting codes and submitting claims to reflect accurately the services rendered to individual patients. Baxter Healthcare Corporation does not guarantee success in obtaining insurance payments. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved by Baxter Healthcare Corporation.

  • Ambulatory Surgical Center (ASC)-covered surgical procedures that may be relevant to the administration of hylenex recombinant include the following:
    CPT
    Descriptor
    67500
    Retrobulbar injection, medication (separate procedure, does not include supply of medication)
    96371
    Injection of medication or other substance into Tenon's capsule
  • Reimbursement for hylenex recombinant and related services will differ based upon the setting of care.
    • For more information about Hospital reimbursement, click here.
    • For more information about Ambulatory Surgical Center (ASC) reimbursement, click here.
  • If you work in an alternate setting of care not listed above, please call the hylenex recombinant reimbursement hotline: 1-888-338-0001

Reimbursement for hylenex recombinant and related services will vary by payer and may differ from the policies described below. Hospitals are encouraged to contact their third-party payers for specific information on their coverage, coding, and payment policies.

Important Risk Information for Healthcare Professionals
Indications

HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for subcutaneous fluid administration; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

Important Risk Information
  • Hypersensitivity to hyaluronidase or any other ingredient in the formulation is a contraindication to the use of this product.
  • Discontinue HYLENEX recombinant (hyaluronidase human injection) if sensitization occurs.
  • Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.
  • Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection.
  • Hyaluronidase should not be used to reduce the swelling of bites or stings.
  • Hyaluronidase should not be applied directly to the cornea.
  • Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated.
  • Furosemide, the benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase.
  • The most frequently reported adverse experiences have been mild local injection site reactions, such as erythema and pain.
  • Hyaluronidase has been reported to enhance the adverse events associated with co-administered drug products.
  • Allergic reactions (urticaria or angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase.
  • Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.
  • When hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action and tends to increase the incidence of systemic reaction.
  • Edema has been reported most frequently in association with subcutaneous fluid administration.
  • The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. As with all parenteral fluid therapy, use the same precautions for restoring fluid and electrolyte balance.
  • During subcutaneous fluid administration, special care must be taken in pediatric patients to avoid over hydration by controlling the rate and total volume of the infusion.
  • When solutions devoid of inorganic electrolytes are given subcutaneously, hypovolemia may occur.